Evidence map›Paper›PMID 41481598›Full record

ArticleJournal of the American Chemical Society2026

Discovery of Supra-Bivalent GSK3β Inhibitory Peptides Containing an ATP-Mimetic Amino Acid.

Sara Haslböck, Alexander A Vinogradov, Chikako Okada, Naoakusa Fujimura, Haruo Aikawa, Toru Sengoku, Hiroaki Suga

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Chemical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sara HaslböckDepartment of Chemistry, Graduate School of Science, The University of Tokyo, Tokyo 113-0033, Japan.ORCID 0000-0002-5849-8046
Alexander A VinogradovDepartment of Chemistry, Graduate School of Science, The University of Tokyo, Tokyo 113-0033, Japan.ORCID 0000-0002-8899-0533
Chikako OkadaDepartment of Biochemistry, Graduate School of Medicine, Yokohama City University, Kanazawa-ku, Yokohama 236-0004, Japan.
Naoakusa FujimuraDepartment of Chemistry, Graduate School of Science, The University of Tokyo, Tokyo 113-0033, Japan.
Haruo AikawaDepartment of Chemistry, Graduate School of Science, The University of Tokyo, Tokyo 113-0033, Japan.ORCID 0000-0003-2536-900X
Toru SengokuDepartment of Biochemistry, Graduate School of Medicine, Yokohama City University, Kanazawa-ku, Yokohama 236-0004, Japan.
Hiroaki SugaDepartment of Chemistry, Graduate School of Science, The University of Tokyo, Tokyo 113-0033, Japan.ORCID 0000-0002-5298-9186

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

De novo discovery of highly selective inhibitors of protein kinases (PKs) remains a significant challenge in drug discovery. Although ATP-site-directed bivalent inhibitors targeting a distinct binding site are an emerging alternative, their rational design is impeded by limited knowledge about allosteric binding sites unique to the target kinase and the complexity of the linker design. Here, we report a strategy that overcomes the above-mentioned issue using a macrocyclic peptide library containing an ATP-mimetic "warhead" amino acid,

Indexed as

Adenosine TriphosphateAmino AcidsDrug DiscoveryGlycogen Synthase Kinase 3 betaPeptidesProtein Kinase InhibitorsHumansModels, MolecularAdenosine TriphosphateAmino AcidsGlycogen Synthase Kinase 3 betaGSK3B protein, humanPeptidesProtein Kinase Inhibitors

Identifiers

PMID41481598
PMCPMC12814355

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.